China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Novartis and Relation's target discovery deal falls under Novartis’ wider ploy to strengthen its immunology portfolio.

Zealand Pharma and OTR Therapeutics are to collaborate to discover and develop therapies for several targets in metabolic diseases.

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...

Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.

The UK's 14.5% drug rebate reduction may help to quell souring pharma sentiments, which stem from the nation's low spending on innovative drugs.

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006 from Lynk Pharmaceuticals.

China’s NMPA has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis ...

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

Formycon and Zydus Lifesciences have entered into an exclusive licensing and supply agreement for FYB206 in the US and Canada ...

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.

We explore the challenges and opportunities of eco-design in parenteral packaging, from alternative feedstocks and carbon ...